Research programme: anticancer therapeutics - Cerylid BiosciencesAlternative Names: CBL 142; CBL 317; CBL 318; CBL-316; CBL-605; CBL-635; CBL-689; CBL-690
Latest Information Update: 07 Feb 2011
At a glance
- Originator Cerylid Biosciences
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Aug 2003 Preclinical trials in Cancer in Australia (unspecified route)